A Case of Rosuvastatin-Induced Rhabdomyolysis: More is Not Better

Abstract

Get full access to this article

View all access options for this article.

References

Antons

Williams

Baker

Phillips

. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006;119:400–9.

Graham

Staffa

Shatin

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585–90.

Wolfe

. Dangers of rosuvastatin identified before and after FDA approval. Lancet 2004;363:2189–90.

McKenney

Davidson

Jacobson

Guyton

. Final conclusions and recommendations of the National Lipid Association Statin Assessment Safety Task Force. Am J Cardiol 2006;97(Suppl):89C–94C.

Brewer

Jr.

Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003;92:23K–29K.

McPherson

Frohlich

Fodor

Genest

. Canadian Cardiovascular Society position statement — recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22:913–27.

Grundy

Cleeman

Merz

Implications of recent clinical trials for the National Cholesterol Education Treatment Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–39.